Side effects of laquinimod were mild and included
mild liver function test elevations, mild arthralgia, elevated
erythrocyte sedimentation rate, and increased
rates of infection in the treated groups. There were
no cardiac events reported with laquinimod treatment
(Comi et al., 2010; Gasperini & Ruggieri, 2011). At
this time, laquinimod will not be submitted to the
FDA for approval. However, plans are underway for
regulatory approval in Europe